{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-006094","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.396017+00:00","generated_at":"2026-06-06T03:49:59.715871+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Telomir Pharmaceuticals completes IPO of 1M shares at $7.00, raising $7M gross","bullets":["Priced 1,000,000 shares at $7.00; gross proceeds $7M. Shares began trading on Nasdaq Feb 9 under TELO.","Underwriters granted 45-day option to purchase up to 150,000 additional shares at IPO price.","Representative's warrants issued to Kingswood for 50,000 shares at $7.00, exercisable after 6-month lock.","Kingswood Investments acted as sole book-running manager; underwriting discount 7% of gross proceeds.","Proceeds to fund development of Telomir-1, a pre-clinical small molecule for age reversal."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-006094","json":"https://secwatch.observer/filing/0001493152-24-006094.json","markdown":"https://secwatch.observer/filing/0001493152-24-006094.md","text":"https://secwatch.observer/filing/0001493152-24-006094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224006094/0001493152-24-006094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224006094/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:49:59.715871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b007858a0de27e6710693d615229621ebfb8f844","claim":"Telomir Pharmaceuticals, Inc. entered into Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC valued at $7,000,000 (effective 2024-02-08).","evidence_excerpt":"On February 8, 2024, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement with Kingswood Investments, division of Kingswood Capital Partners, LLC (“Kingswood”) on behalf of itself and as representative of the underwriters named therein (the “Underwriting Agreement”), pursuant to which the Company issued and sold, in an underwritten public offering (the “Public Offering”), 1,000,000 shares of common stock, no par value (“Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315224006094/0001493152-24-006094-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Kingswood Investments, division of Kingswood Capital Partners, LLC"},{"label":"Value","value":"$7,000,000"},{"label":"Effective","value":"2024-02-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}